MARK SAXON: Open Payments
NPI 1255389326 · KINGSTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,983 in 163 payments from 17 companies in 2025. Trend: 2023 $3,066 · 2024 $3,102 · 2025 $2,983
Food & beverage: $2,872Education: $111
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 22 | $362 |
| Otsuka America Pharmaceutical, Inc. | 21 | $362 |
| ABBVIE INC. | 21 | $350 |
| Teva Pharmaceuticals USA, Inc. | 16 | $346 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $284 |
| Janssen Pharmaceuticals, Inc | 12 | $270 |
| E.R. Squibb & Sons, L.L.C. | 16 | $262 |
| Axsome Therapeutics, Inc. | 13 | $251 |
| Vanda Pharmaceuticals Inc. | 4 | $116 |
| Alkermes, Inc. | 6 | $111 |
Products named: INGREZZA, VRAYLAR, CAPLYTA, COBENFY, REXULTI, AUSTEDO XR, INVEGA SUSTENNA, Auvelity.
Industry payments across PA — which companies pay providers there.
